Today, a brief rundown of news from GSK and Roivant, as well as updates from Zealand Pharma, Eli Lilly and Xencor that you may have missed. GSK will not advance an experimental vaccine for the herpes ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

Credit: CeltStudio/Shutterstock. Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK‘s new drug application (NDA) for Blenrep (belantamab mafodotin) to treat patients ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures. GSK and iTeos ...

At the European Society for Medical Oncology (ESMO) Congress 2024, GSK and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...